Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd. have announced an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of atopic dermatitis and asthma.
Scinai Immunotherapeutics Ltd. has released promising preclinical results of its innovative anti‑IL‑17 VHH antibody (NanoAb) as a local treatment for mild to moderate plaque psoriasis.
Researchers from Mitsubishi Tanabe Pharma Corp. and affiliated organizations have described the discovery and preclinical evaluation of a novel adiponectin receptor (AdipoR)-activating monoclonal antibody, named AdipoRaMab, being developed for the treatment of type 2 diabetes and nonalcoholic steatohepatitis (NASH).
Seismic Therapeutic Inc. has closed a $121 million series B financing to support progression of the company’s two lead programs through clinical proof of mechanism.
Proteoglycan glypican-1 (GPC1) is a tumor-associated antigen that is highly expressed in tumor tissues from patients with pancreatic ductal adenocarcinoma (PDAC), while its expression is very low on benign neoplastic lesions, chronic pancreatitis and normal adult pancreatic tissue. Researchers from Centro Di Riferimento Oncologico (CRO Aviano) and L'Università degli studi di Trieste have reported the development and preclinical characterization of AT-101, a novel complement-fixing IgM antibody targeting GPC1, as a potential immunotherapy candidate for the treatment of PDAC.
Anaptysbio Inc. has signed an exclusive license agreement for Centessa Pharmaceuticals plc’s blood dendritic cell antigen 2 (BDCA-2) modulator antibody portfolio, including lead asset CBS-004 (to be renamed ANB-101) and related family of backup antibodies, for the treatment of autoimmune and inflammatory diseases.
Researchers from Apeximmune Therapeutics Inc. presented the discovery and preclinical evaluation of AIM-104, a novel potent pan-allele anti-SIRPα antibody for the treatment of cancer.
Scirhom GmbH has submitted a clinical trial application (CTA) for its lead candidate, SR-878, an antibody designed to target inactive rhomboid protein 2 (iRhom2) as a therapeutic strategy for numerous autoimmune disorders.
Vectory Therapeutics BV has closed a €129 million ($138 million) series A financing to advance its vectorized antibody programs in neurodegenerative diseases.
RSS
